Product Description
Voxilaprevir is an orally bioavailable inhibitor of the hepatitis C virus (HCV) non-structural protein 3/non-structural protein 4A (NS3/NS4A) serine protease, with antiviral activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Voxilaprevir)
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hepatitis C|Hepatitis A|Hepatitis C, Chronic|Liver Cancer|Hepatocellular Carcinoma|Liver Cirrhosis|Coinfection
Phase 3: Hepatitis A|Hepatitis C|Communicable Diseases|Hepatitis C, Chronic
Phase 2: Hepatitis C|Communicable Diseases|Hepatitis C, Chronic|Hepatitis A
Phase 1: Hepatitis C|Kidney Diseases|Hepatitis C, Chronic|Communicable Diseases|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2014-004674-42 | P4 |
Unknown status |
Hepatitis C, Chronic |
2030-11-20 |
|
| ChiCTR2200064110 | N/A |
Not yet recruiting |
Liver Cirrhosis|Hepatitis, Chronic |
2026-06-30 |
|
| LCYJ-2023-005 | N/A |
Recruiting |
Hepatitis C, Chronic |
2026-02-28 |
|
| NCI-2023-00828 | P4 |
Terminated |
Liver Cancer|Hepatocellular Carcinoma|Hepatitis C, Chronic |
2024-08-29 |